DAWN Stock Summary and Trading Ideas (Day One Biopharmaceuticals | NASDAQ:DAWN)

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.

Day One Biopharmaceuticals trades on the NASDAQ stock market under the symbol DAWN.

As of April 1, 2026, DAWN stock price declined to $21.42 with 938,505 million shares trading.

DAWN has a beta of 0.35, meaning it tends to be less sensitive to market movements. DAWN has a correlation of 0.00 to the broad based SPY ETF.

DAWN has a market cap of $2.21 billion. This is considered a Mid Cap stock.

Last quarter Day One Biopharmaceuticals reported $54 million in Revenue and -$.21 earnings per share. This beat revenue expectation by $5 million and missed earnings estimates by -$.05.

In the last 3 years, DAWN traded as high as $21.46 and as low as $5.64.

The top ETF exchange traded funds that DAWN belongs to (by Net Assets): IWM, VTI, XBI, IWN, IBB.

DAWN has outperformed the market in the last year with a price return of +170.1% while the SPY ETF gained +18.5%. DAWN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +129.8% and +0.6%, respectively, while the SPY returned -3.6% and -2.1%, respectively.

DAWN support price is $20.70 and resistance is $22.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DAWN shares will trade within this expected range on the day.